The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 29 results:
Author [ Title(Asc)] Type Year
Filters: Author is Imprialos, Konstantinos P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters.. JAMA Intern Med. 177(9), 1393.
S
Stavropoulos, K., Imprialos K. P., Doumas M., Athyros V. G., & Karagiannis A. (2018).  Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. J Hypertens. 36(3), 701.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., & Karagiannis A. I. (2017).  Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. J Neurol Neurosurg Psychiatry. 88(3), 249-253.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2018).  Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs.. Cardiovasc Hematol Disord Drug Targets. 18(2), 83-85.
Imprialos, K. P., Sarafidis P. A., & Karagiannis A. I. (2015).  Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?. J Hypertens. 33(11), 2185-97.
Stavropoulos, K., Imprialos K. P., Stavropoulos N., Bouloukou S., Kerpiniotis G., Dimitriadis K., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.. Cardiovasc Hematol Disord Drug Targets. 18(2), 120-126.
Imprialos, K. P., Stavropoulos K., Stavropoulos N., Patoulias D., Petidis K., Grassos C., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.. Cardiovasc Hematol Disord Drug Targets. 18(2), 104-113.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2018).  Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.. J Clin Hypertens (Greenwich). 20(1), 65-68.
R
Koutsampasopoulos, K., Vogiatzis I., Ziakas A., Papadopoulos C., Imprialos K. P., Stavropoulos K., et al. (2019).  Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure.. J Sex Med.
Imprialos, K. P., Boutari C., Stavropoulos K., Sampani E., & Karagiannis A. I. (2016).  Renin-Angiotensin System Inhibitors: Do They Have the Same Impact at All Ages?. J Clin Hypertens (Greenwich). 18(8), 828.
Doumas, M., Stavropoulos K., Imprialos K. P., Athyros V. G., & Karagiannis A. (2018).  Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. J Clin Hypertens (Greenwich). 20(4), 634-636.
Stavropoulos, K., Imprialos K. P., Athyros V. G., & Doumas M. (2018).  Renal resistive index for renovascular hypertension: In the quest of the Holy Grail.. J Clin Hypertens (Greenwich). 20(3), 589-591.
P
Stavropoulos, K., Imprialos K. P., Katsiki N., Petidis K., Kamparoudis A., Petras P., et al. (2018).  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich). 20(5), 942-948.
Imprialos, K. P., Stavropoulos K., Doumas M., Skalkou A., Zografou I., & Athyros V. G. (2018).  The potential role of statins in treating liver disease.. Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
Doumas, M., Imprialos K. P., Stavropoulos K., & Athyros V. G. (2018).  Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. J Clin Hypertens (Greenwich). 20(3), 469-471.
O
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med. 377(25), 2502.
L
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Liraglutide and Renal Outcomes in Type 2 Diabetes.. N Engl J Med. 377(22), 2196.
I
Stavropoulos, K., Imprialos K. P., Doumas M., Karagiannis A., & Papademetriou V. (2019).  Insomnia and hypertension: A misty landscape.. J Clin Hypertens (Greenwich). 21(6), 835-837.
E
Doumas, M., Imprialos K. P., & Stavropoulos K. (2018).  Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.. N Engl J Med. 378(10), 967.
Imprialos, K. P., Stavropoulos K., Doumas M., Karagiannis A., & Athyros V. G. (2017).  The effect of SGLT2 inhibitors on cardiovascular events and renal function.. Expert Rev Clin Pharmacol. 10(11), 1251-1261.
D
Athyros, V. G., Doumas M., Imprialos K. P., Stavropoulos K., Georgianou E., Katsimardou A., et al. (2018).  Diabetes and lipid metabolism.. Hormones (Athens). 17(1), 61-67.
Stavropoulos, K., Imprialos K. P., Faselis C., Karagiannis A., & Papademetriou V. (2019).  Determinants of pulse wave velocity index and potential implementations.. J Clin Hypertens (Greenwich).
C
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., Athyros V. G., & Karagiannis A. I. (2016).  Current challenges in antihypertensive treatment in the elderly.. Pol Arch Med Wewn. 126(7-8), 540-51.
Stavropoulos, K., Imprialos K. P., Doumas M., & Athyros V. G. (2018).  Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. J Clin Hypertens (Greenwich). 20(2), 255-257.
Stavropoulos, K., Imprialos K. P., Boutari C., Athyros V. G., & Karagiannis A. I. (2016).  Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. J Clin Hypertens (Greenwich). 18(10), 1073.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.